Stockhead | LTR Pharma firms up study for erectile dysfunction with patient recruitment

LTR Pharma has been featured in Stockhead following the announcement that patient recruitment for its pivotal clinical study of SPONTAN® has opened.

An excerpt:

“The global ED market is forecast to increase to US$5.94 billion by 2028, growing at a CAGR of 7.1%.

With such strong demand for effective ED treatments, LTP hit the Aussie bourse on December 11, 2023, after a heavily oversubscribed IPO, including strong institutional support with eight fund managers on the register.

It rose 65% in its first month as a public company to be the top ASX IPO performer of 2023.”

Click here to read the article.